Abstract:Background: Long QT syndrome 3 (LQT3) is caused by SCN5A mutations. Late sodium current (late INa) inhibitors are current-specific to treat patients with LQT3, but the mechanisms underlying mexiletine (MEX) -sensitive (N1325S and R1623Q) and -insensitive (M1652R) mutations remains to be elucidated.Methods: LQT3 patients with causative mutations were treated with oral MEX following i.v. lidocaine. Whole-cell patch-clamp techniques and molecular remodeling were used to determine the mechanisms underlying the sensitivity to MEX.Results: Intravenous administration of lidocaine followed by MEX orally in LQT patients with N1325S and R1623Q sodium channel mutation shortened QTc interval, abolished arrhythmias, and completely normalized the ECG. In HEK293 cells, the steady-state inactivation curves of the M1652R channels were rightward shifted by 5.6 mV relative to the WT channel. In contrast, the R1623Q mutation caused a leftward shift of the steady-state inactivation curve by 15.2 mV compared with WT channel, and N1325S mutation did not affect steady-state inactivation (n = 5–13, P < 0.05). The extent of the window current was expanded in all three mutant channels compared with WT. All three mutations increased late INa with the greatest amplitude in the M1652R channel (n = 9–15, P < 0.05). MEX caused a hyperpolarizing shift of the steady-state inactivation and delayed the recovery of all three mutant channels. Furthermore, it suppressed late INa in N1325S and R1623Q to a greater extent compared to that of M1652R mutant channel. Mutations altered the sensitivity of Nav1.5 to MEX through allosteric mechanisms by changing the conformation of Nav1.5 to become more or less favorable for MEX binding. Late INa inhibitors suppressed late INa in N1325S and R1623Q to a greater extent than that in the M1652R mutation (n = 4–7, P < 0.05).Conclusion: The N1325S, R1623Q, and M1652R mutations are associated with a variable augmentation of late INa, which was reversed by MEX. M1652R mutation changes the conformation of Nav1.5 that disrupt the inactivation of channel affecting MEX binding, corresponding to the poor response to MEX. The lidocaine test, molecular modeling, and drugs screening in cells expressing mutant channels are useful for predicting the effectiveness of late INa inhibitors.

Why Does the Inner-Helix Mutation A413C Double the Stoichiometry of Kv1.3 Channel Block by Emopamil but Not by Verapamil?

Investigation of the phenylalkylamine binding site in hKv1.3 (H399T), a mutant with a reduced C-type inactivated state

Kinetic Aspects of Verapamil Binding (On-Rate) on Wild-Type and Six hKv1.3 Mutant Channels

Effects of Calcium-Binding Sites in the S2–S3 Loop on Human and Nematostella Vectensis TRPM2 Channel Gating Processes

KCNE4-dependent modulation of Kv1.3 pharmacology

Homology Modeling Identifies C-Terminal Residues That Contribute to the Ca2+ Sensitivity of A Bkca Channel

Structure of a Ca2 +/cam:Kv7.4 (KCNQ4) B-Helix Complex Provides Insight into M Current Modulation

Inhibitory Actions of the Phosphatidylinositol 3-Kinase Inhibitor LY294002 on the Human Kv1.5 Channel.

Structural Basis of a Potent Peptide Inhibitor Designed for Kv1.3 Channel, a Therapeutic Target of Autoimmune Disease

Open channel block of Kv1.5 channels by HMQ1611

Comparative structural analysis of human Na<sub>v</sub>1.1 and Na<sub>v</sub>1.5 reveals mutational hotspots for sodium channelopathies

Phenylalkylamines in calcium channels: computational analysis of experimental structures

Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs

A novel current pathway parallel to the central pore in a mutant voltage-gated potassium channel

Dual effects of mefenamic acid on the IKs molecular complex

Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3

Impact Of Phosphomimetic And Non-Phosphorylatable Mutations Of Phospholemman On L-Type Calcium Channels Gating In Hek 293t Cells

Effect of K+ and Rb+ on the action of verapamil on a voltage-gated K+ channel, hKv1.3: implications for a second open state?

Characterization of the σ-Pore in Mutant hKv1.3 Potassium Channels

Permeation and block of the Kv1.2 channel examined using brownian and molecular dynamics

Diverse biophysical mechanisms in voltage-gated sodium channel Nav1.4 variants associated with myotonia